The 21st century form of vitamin E-tocotrienol

Current Pharmaceutical Design

Volumn 17, Issue 21, 2011, Pages 2196-2205

  Bardhan, Jayeeta ^a   Chakraborty, Runu ^a   Raychaudhuri, Utpal ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

Antioxidant; Cancer; Cholesterol; Signaling; Tocotrienol

Indexed keywords

ALPHA TOCOTRIENOL;

ALZHEIMER DISEASE; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BONE DENSITY; BRAIN DAMAGE; BREAST CANCER; CELL CYCLE ARREST; DEGENERATIVE DISEASE; DRUG ABSORPTION; DRUG MECHANISM; GENETIC DISORDER; HEART PROTECTION; HUMAN; HUNTINGTON CHOREA; LIVER CANCER; LUNG CANCER; NERVE INJURY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROSTATE CANCER; SKIN CANCER; STOMACH CANCER; TRAUMATIC BRAIN INJURY;

ANIMALS; ANTIOXIDANTS; DIETARY SUPPLEMENTS; HUMANS; MOLECULAR STRUCTURE; PREVENTIVE MEDICINE; TOCOTRIENOLS;

EID: 80052193199     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211796957472     Document Type: Article

References (124)

1. Sen CK, Khanna S, Roy S. The other half of the natural vitamin E family. Molecular Aspects of Medicine 2007; 28: 692-728.
2. Theriault A, Chao J, Wang Q, Gapor A, Adeli K. Tocotrienol: a review of its therapeutic potential. Clinical Biochemistry 1999; 32: 309-319.
3. Tan B, Appropriate Spectrum Vitamin E and New Perspectives on Desmethyl Tocopherols and Tocotrienols. JANA 2005; 8 No. 1: 35-42.
4. Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. Life Science 2006; 78(18): 2088-2098.
5. Watson RR, Preedy VR, Eds. Tocotrienols vitamin E beyond tocopherols. New York: Taylor& Francis Group 2009.
6. [Hosomi, A, Arita, M., Sato Y., Kiyose, C., Ueda, T., Igarashi, O., Arai, H, Inoue, K. Affinity for alpha-tocopherol transfer protein as determinant of the biological activities of Vitamin E analogs. FEBS Lett. 1997; 409: 105-108.
7. [Schultz M, Leist M, Petrzika M, Gassmann B, Brigelius-Flohe' R. Novel urinary metabolite of α-tocopherol, 2,5,7,8-tetramethyl-2(2'-carboxyethyl)-6-hydroxychroman, as an indicator of an adequate vitamin E supply? Am. J. Clin. Nutr. 1995; 62: 1527S-1534S.
8. Lodge JK, Ridlington J, Leonard S, Vaule H, Traber MG. α-and γ-tocotrienol are metabolized to carboxyethyl-hydroxychroman derivatives and excreted in urine. Lipids 2001; 36: 46-48.
9. [Packer L, Weber SU, Rimbach G. Molecular aspects of α-tocotrienol antioxidant action and cell signaling. Journal of Nutrition 2001; 131: 369S-373S.
10. Hayes KC, Pronezuk A, Liang JS. Differences in the plasma transport and tissue concentrations of tocopherol and tocotrienol: observations in human and hamsters. Proc. Soc. Exp. Biol. Med. 1993; 202: 353-359.
11. Ikeda S, Tohyama T, Yoshimura H, Hamamura K, Abe K, Yamashita K. Dietary alpha tocopherol decreases alpha tocotrienol but not gamma tocotrienol concentration in rats. The Journal of Nutrition 2003; 133: 428-434.
12. Sen CK, Khanna S, Roy S, Packer L. Molecular Basis of Vitamin E Action. The Journal of Biological Chemistry 2000; 275: 13049-13055.
13. Serbinova E, Kagan V, Han D, Packer L. Free radical recycling and intermembrane mobility in the. and properties of α -tocopherol and α-tocotrienol. Free Radic. Biol. Med. 1991; 10: 263-275.
14. Constantinescu A., Han D. & Packer L. Vitamin E recycling in human erythrocyte membranes. J. Biol. Chem. 1993; 268: 10906-10913.
15. Kagan VE, Serbinova EA, Forte T, Scita G. & Packer L. Recycling of vitamin E in human low density liporoteins. J. Lipid Res. 1992; 33: 385-397.
16. Suarna C, Hood RL, Dean RT. & Stocker R. Comparative antioxidant activity of tocotrienols and other natural lipid-soluble antioxidants in a homogeneous system, and in rat and human lipoproteins. Biochim. Biophys. Acta 1993; 1166: 163-170.
17. Verlangieri A.J. & Bush MJ. Effects of d-a-tocopherol supplementation on experimentally induced primate atherosclerosis. J. Am. Coll. Nutr. 1992; 11: 131-138.
18. Kamat JP, Devasagayam TP. Tocotrienol from palm oil as potent inhibitors of lipid peroxidation in rat brain mitochondria. Neurosci. Lett. 1995; 195(3): 179-82.
19. Ahmad NS, Khalid BA, Luke DA, Ima NS.Tocotrienol offers better protection than tocopherol from free radical induced damage of rat bone. Clin. Exp. Pharmacol. Physiol. 2005; 32(9): 761-70.
20. Yoshida Y, Itoh N, Hayakawa M, Piga R, Cynshi O, Jishage K, Niki E. Lipid peroxidation induced by carbon tetrachloride and its inhibition by antioxidant as evaluated by an oxidative stress marker HODE. Toxicol. Appl. Pharmacol. 2005; 208(1): 87-97.
21. Yu FL, Gapor A, Bender W. Evidence for the preventive effect of the polyunsaturates phytol side chain in tocotrienols on 17 beta -estradiol epoxidtion.Cancer Detect Prev. 2005; 29(4): 383-8.
22. Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutarylcoenzyme A reductase. J. Biol. Chem. 1993; 268: 11230-11238
23. Song B, Boyd R. Insig-dependent Ubiquitination and Degradation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Stimulated by_δ-and _γ-Tocotrienols. JBC 2006; 281(35): 25054-25061.
24. Ahn KS, Sethi G, Krishnan K,Aggarwal BB. G{cyrillic}-Tocotrienol inhibits nuclear factor-κβ signaling pathway through inhibition of receptor interacting protein and TAK 1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis. Journal of Biological Chemistry 2007; 282(1): 809-820.
25. Ahn KS, Sethi G, and Aggarwal BB (2007) Simvastatin potentiates TNF-alpha induced apoptosis through the down-regulation of NFkappaB-dependent antiapoptotic gene products: role of IkappaBalpha kinase and TGF-beta-activated kinase-1. J Immunol 178: 2507-2516.
26. Cominacini L, Anselmi M, Garbin U, Frata Pasini A, Stanieri C, Fusaro M, Nava C, Agostoni P, Keta D, Zardini P, Sawamura T, Lo Cascio V. Enhanced Plasma Levels of Oxidized Low-Density Lipoprotein Increase Circulating Nuclear Factor-Kappa B Activation in Patients With Unstable Angina. J. Am. Coll. Cardiol. 2005; 46: 799-806.
27. Chen CW, Cheng HH. A rice bran oil diet increases LDL-receptor and HMG Co A reductase mRNA expressions and insulin sensitivity in rats with streptozotocin/nicotinamide induced type 2 diabetes. J. Nutr. 2006; 136: 1472-1476.
28. Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 2002; 23: 443-63.
29. Cheema SK, Agellon LB. The murine and human cholesterol 7 alpha hyroxylase gene promoters are differentially responsive to regulation by fatty acids mediated via peroxisome proliferators-activated receptor alpha. J BIOL. Chem. 2000; 275: 12530-6
30. Dietschy JM, Turley SD, Spady DK. Role of liver in maintainence of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993; 34: 1637-59.
31. Raederstorff D, Elste V, Aebischer C, Weber P. Effect of either Gamma-Tocotrienol or a Tocotrienol Mixture on the Plasma Lipid Profile in Hamsters. Annals of Nutrition & Metabolism 2002; 46(1): 17-23
32. Watkins T, Lenz P, Gapor A, Struck M, Tomeo, Bierenbaum M. -Tocotrienol as a hypocholesterolemic and antioxidant agent in rats fed atherogenic diets. Lipids 1993; 28: 1113-1118.
33. Ha T, Kim S, Kim I, Lee H, Kim H. Bioactive components in rice bran oil improve lipid profiles in rats fed a high -cholesterol diet. Nutrition Research 2005; 25(6): 597-606.
34. [Qureshi AA, Qureshi N, Hasler-Rapacz JO, Weber FE, Chaudhary V, Crenshaw TD, Gapor A, Ong AS, Chong YH, Peterson D, Rapacz J. Dietary tocotrienols reduce concentrations of plasma cholesterol, apolipoprotein B, thromboxane B2, and platelet factor 4 in pigs with inherited hyperlipidemias. Am. J. Clin. Nutr. 1991; 53: 1042S-1046S.
35. O'Byrne DO, Grundy S, Packer L, Devaraj S, Baldenius K, Hoppe P, Krämer K, Jialal I, Traber MG. Studies of LDL oxidation following alpha-, gamma-or delta-tocotrienyl acetate supplementation of hypercholesterolemic humans. Free Radic. Biol. Med. 2000; 29: 834-845
36. Das S, Powell SR, Wang P, Divald A, Nesaretnam K, Tosaki A, Cordis GA, Maulik N, Das DK. Cardioprotection with palm tocotrienol: antioxidant activity of tocotrienol is linked with its ability to stabilize proteasomes. Am J Physiol Heart Circ Physiol 2005; 289: H361-H367.
37. [Das S, Tosaki A, Juhasz B, Lekli I, Varadi J, Nesaretam K, Maulik N, and Das D. Tocotrienols in Cardioprotection: Role of Different Isomers; The FASEB Journal 2007; 21: 857.2.
38. Gurusamy N, Goswami S, Malik G, Das DK. Oxidative injury induces selective rather than global inhibition of proteasomal activity; Journal of Molecular and Cellular Cardiology 2008; 44: 419-428.
39. Das M, Das S, Wang P, Powell SR, Das DK. Caveolin and proteasome in tocotrienol mediated myocardial protection. Cell Physiol Biochem 2008; 22: 287-294.
40. [] Powell SR, Wang P, Katzeff HL, Shrinagarpure R, Teoh C, Khaliulin I, Das DK, Schwalb H. Oxidized and ubiquitinated proteins may predict recovery of post ischemic cardiac function: Essential role of proteasome. Antioxid Redox Signal 2005; 7: 538-546.
41. Das M, Cui J, Das DK. Generation of survival signal by differential interaction of p38MAPKα and p38MAPKβ with caveolin-1 and caveolin-3 in the adapted heart. J Mol Cell Cardiol 2007; 42: 206-213.
42. Das S, Powell SR, Wang P, Divald A, Nesaretnam K, Tosaki A, Cordis GA, Maulik N, Das DK.Cardioprotection with palm tocotrienol: antioxidant activity of tocotrienol is linked with its ability to stabilize proteasome. Am. J. Physiol. Heart Circ Physiol 2005; 289: H361-H367.
43. Sumbayev VV, Yasinska IM. Regulation of Map kinase dependent apoptotic pathway: implication of reactive oxygen and nitrogen species. Arch Biochem Biophys. 2005; 436: 406-412.
44. Hattori R, Otani H, Uchiyama T, Imamura H, Cui J, Maulik N, Cordis GA, Zhu L, Das DK. Src-tyrosine kinase is the trigger but not the mediator of Ischemic Preconditioning. Am J Physiol Heart Circ Physiol. 2001; 282: H1066-H1074.
45. Muthuswamy SK, Siegel PM, Danjort DL, Webster MA, Muller WJ. Mammary tumors expressing the neu proto-oncogen posses elevated c-Src tyrosine kinase activity. Mol Cell Biol. 1994; 14: 735-743.
46. Barnekow A, Paul E, Schartl M. Expression of the c-src protooncogene in human skin tumors. Cancer Res. 1987; 47: 235-240.
47. Choi AMK. Heme oxygenase-1 protects the heart. Circ Res. 2001; 89: 105-107.
48. Jones SP, Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol. 2006; 40: 16-23.
49. Murphy E, Steenbergen C. Cardioprotection in females: role of nitric oxide and altered gene expression. Heart Fail Rev. 2008; 12: 293-300.
50. Fumitaka O, Asami H, Toshiaki K, Hiroshi K, Shuji K,Akinori A.α-Tocotrienol provides the most potent neuroprotection among vitamin E analogs on cultured striatal neurons.Neuropharmacology 2004; 47: 904-915.
51. Kamat JP, Devasagayam TP. Tocotrienols from palm oil as potent inhibitors of lipid peroxidation and protein oxidation in rat brain mitochondria. Neurosci. Lett 1995; 195: 179-182.
52. Maher P, Hanneken A. The Molecular Basis of Oxidative Stress-Induced Cell Death in an Immortalized Retinal Ganglion Cell Line. IOVS 2005; 46: 749-757.
53. Osborne NN, Ugarte M, Chao M, et al. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol. 1999; 43: S102-S128.
54. Rothman SM. The neurotoxicity of excitatory amino acids is produced by passive chloride influx. J. Neurosci. 1985; 5: 1483-1489.
55. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol. 1986; 19: 105-111.
56. Tan S, Schubert D, Maher P. Oxytosis: a novel form of programmed cell death. Curr Top Med Chem. 2001; 1: 497-506.
57. Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT. Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron. 1989; 2: 1547-1558.
58. [Khanna S, Roy S, Slivka A, Craft TKS, Chaki S, Rink C, Notestine MA, De Vries AC, Parinandi NL, Sen CK. Neuroprotective Properties of the Natural Vitamin E α -Tocotrienol. Stroke 2005; 36: e144-e152.
59. [Palm-tocotrienol Rich Fraction (TRF) Is a More Effective Inhibitor of LDL Oxidation and Endothelial Cell Lipid Peroxidation than atocopherol In Vitro. Sokhini, M., Mutalib, A., et al. Food Research Internal 36: 405-413, 2003Â.
60. Khanna S, Roy S, Ryu H, Bahadduri P, Swaan PW, Ratan RR, Sen CK. Molecular basis of vitamin E action: tocotrienol modulates 12-lipoxygenase, a key mediator of glutamate-induced neurodegeneration. J Biol Chem. 2003; 278: 43508-43515.
61. Paul R, Zhang ZG, Eliceiri BP, Jiang Q, Boccia AD, Zhang RL, Chopp M, Cheresh DA. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat Med. 2001; 7: 222-227.
62. Sylvester PW, Shah SJ. Mechanisms mediating the antiproliferative and apoptotic effects of vitamin E in mammary cancer cells. Front Biosci. 2005; 10: 699-709.
63. Ahn KS, Sethi G, Krishnan K, Aggarwal BB. γ-Tocotrienol inhibits nuclear factor -κβ signaling pathway through inhibition of receptor-interacting protein and TAK 1 leading to suppression of antiapoptotic gene products and potentiation of apoptosis.The Journal of Biological Chemistry 2007; 282 (1): 809-820.
64. Wada S, Satomi Y, Murakoshi M, Noguchi N, Yoshikawa T, Nishino H. Tumor suppressive effects of tocotrienol in vivo and in vitro Cancer Lett. 2005; 229: 181-191
65. Parker RA, Pearce BC, Clark RW, Gordon DA,Wright JJ. Tocotrienols regulate cholesterol production in mammalian cells by post-translational suppression of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. J. Biol.Chem. 1993; 268: 11230-11238.
66. Agarwal MK, Agarwal ML, Athar M, Gupta S. Tocotrienol-rich fraction of palm oil activates p53, modulates Bax/Bcl2 ratio and induces apoptosis independent of cell cycle association.Cell Cycle 2004; 3: 205-211.
67. Shah S, Sylvester PW. Tocotrienol-induced caspase-8 activation is unrelated to death receptor apoptotic signaling in neoplastic mammary epithelial cells. Exp. Biol. Med. (Maywood) 2004; 229: 745-755.
68. Naito Y, Shimozawa M, Kuroda M, Nakabe N, Manabe H, Katada K, Kokura S, Ichikawa H, Yoshida N, Noguchi N, Yoshikawa T. Tocotrienols reduce 25-hydroxycholesterol-induced monocyteendothelial cell interaction by inhibiting the surface expression of adhesion molecules. Atherosclerosis 2005; 180: 19-25.
69. Theriault A, Chao JT, Gapor A. Tocotrienol is the most effective vitamin E for reducing endothelial expression of adhesion molecules and adhesion to monocytes. Atherosclerosis 2002; 160: 21-30.
70. [Noguchi N, Hanyu R, Nonaka A, Okimoto Y, Kodama T. Inhibition of THP-1 cell adhesion to endothelial cells by alpha-tocopherol and alpha-tocotrienol is dependent on intracellular concentration of the antioxidants. Free Radical Biol. Med. 2003; 34: 1614-1620.
71. Eitsuka T, Nakagawa K, Miyazawa T. Down-regulation of telomerase activity in DLD-1 human colorectal adenocarcinoma cells by tocotrienol Biochem. Biophys. Res. Commun. 2006; 348: 170-175.
72. Miyazawa T, Inokuchi H, Hirokane H, Tsuzuki T, Nagakawa K, Igarashi M. Anti-angiogenic potential of tocotrienol in vitro. Biochemistry (Mosc.) 2004; 69: 67-69.
73. Ahn KS, Sethi G, Aggarwal BB. Simvastatin potentiates TNF-α-induced apoptosis through the down-regulation of NF-κB-dependent antiapoptotic gene products: role of IκBα kinase and TGF-betaactivated kinase-1. J Immunol. 2007; 178: 2507-2516.
74. Song, B.L., and DeBose-Boyd, R. A., Insig-dependent Ubiquitination and Degradation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Stimulated by δ-and γ-Tocotrienols. J. Biol. Chem. 2006; 281: 25054-25061.
75. Nesaretnam K, Koon TH, Kanga Rani Selvaduray KR, Bruno RS, Ho E. Modulation of cell growth and apoptosis response in human prostate cancer cells supplemented with tocotrienols. Eur. J. Lipid Sci. Technol. 2008; 110: 23-31.
76. Xu WL, Liu JR, Liu HK, Qi GY, Sun XR, Sun WG, Chen BQ. Inhibition of proliferation and induction of apoptosis by γ-tocotrienol in human colon carcinoma HT-29 cells. Nutrition 2009; 25: 555-566.
77. Galli F, Stabile AM, Betti M, Conte C, Pistilli A, Rende M, Floridi A, Azzi A. The effect of alpha-and gamma-tocopherol and their carboxyethyl hydroxychroman metabolites on prostate cancer cell proliferation. Arch. Biochem. Biophys. 2004; 423: 97-102.
78. Nesaretnam K., Stephen R., Dils R., Darbre P. Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen recetor status. Lipids 1998; 33: 461-9.
79. Yoshihisa Y, Haruna S, Keiko F, Itsumaro K, Tomio I, Kazuhiko Y, Kiyokazu H, Tomohiro Y. Induction of cytotoxicity in human lung adenocarcinoma cells by 6-O-carboxypropyl-α-tocotrienol, a redoxsilent derivative of α-tocotrienol. International journal of cancer 2005; 115: 839-846.
80. Korehito K, Kayono H, Yoshihisa Y, Itsumaro K, Kiyokazu H, Jun T, Wakiko K, Nantiga V, Tomohiro Y. A redox-silent analogue of tocotrienol inhibits hypoxic adaptation of lung cancer cells. Biochemical and Biophysical Research Communications 2008; 365: 875-881.
81. Rahmat A, Ngah WZ, Shamaan NA, Gapor A, Abdul Kadir K. Long-term administration of tocotrienols and tumor-marker enzyme activities during hepatocarcinogenesis in rats. Nutrition 1993; 9: 229-32.
82. Wada S, Satomi Y, Murakoshi M, Noguchi N, Yoshikawa T, Nishino H. Tumor suppressive effects of tocotrienol in vivo and in vitro. Cancer Lett. 2005; 229: 181-91.
83. Weber C, Podda M, Rallis M, Thiele JJ, Traber MG, Packer L. Efficacy of Topically Applied Tocopherols and Tocotrienols in Protection of Murine Skin From Oxidative Damage Induced by UVirradiation. Free Radic. Biol. Med. 1997; 22: 761-769.
84. Traber MG, Podda M, Weber C, Thiele J, Rallis M, Packer L. Diet derived topically applied tocotrienols accumulate in skin and protect the tissue against uv light-induced oxidative stress. Asia Pacific J. Clin. Nutr. 1997; 6: 63-67.
85. Chang PN, Yap WN, Lee DT, Ling MT, Wong YC, Yap YL (2009).Evidence of gamma-tocotrienol as an apoptosis-inducing, invasionsuppressing, and chemotherapy drug-sensitizing agent in human melanoma cells. Nutrition and Cancer 2009; 61: 357-66.
86. Yap WN, Chang PN, Han HY, Lee DTW, Ling MT, Wong YC, Yap YL. γ-Tocotrienol suppresses prostate cancer cell proliferation and invasion through multiple-signalling pathways. British Journal of Cancer 2008; 99: 1832-1841
87. Srivastava J.K., Gupta S. Tocotrienol-rich fraction of palm oil induces cell cycle arrest and apoptosis selectively in human prostate cancer cells. Biochem Biophys Res Commun 2006; 346: 447-53
88. Liu HK, Wang Q. Li Y, Sun WG, Liu JR, Yang YM, Xu WL, Sun XR, Chen BQ. Inhibitory effects of γ-tocotrienol on invasion and metastasis of human gastric adenocarcinoma SGC-7901 cells. The Journal of Nutritional Biochemistry 2010; 21: 206-213.
89. Miyazawa T., Inokuchi, H, Hirokane, H., Tsuzuki, T., Nakagawa, K., Igarashi, M. Anti-angiogenic potential of tocotrienol in vitro. Biochemistry (Moscow) 2004; 69: 85-88.
90. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235: 442-447.
91. Vincent L, Chen W, Hong L, Mirshahi F, Mishal Z, Mirshahi-Khorassani T, Vannier JP, Soria J, Soria C. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect FEBS Lett 2001; 495: 159-166.
92. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA Circ. Res. 2002; 91: 143-150.
93. Shono T, Ono M, Izumi H, Jimi SI, Matsushima K, Okamoto T, Kohno K, Kuwano M. Involvement of the transcription factor NFkappaB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol. Cell. Biol. 1996; 16: 4231-4239.
94. Miyazawa T, Tsuzuki T, Nakagawa K, Igarashi M: Antiangiogenic potency of vitamin E. Ann N Y Acad Sci; 2004; 1031: 401-4
95. [Sylvester P, Theriault A. Role of tocotrienols in the prevention of cardiovascular disease and breast cancer. Curr Top in Nutra Res. 2003; 1(2): 121-136.
96. He L, et al. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. J Nutr. 1997; 127: 668-674.
97. Mo HB, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Bio Med. 2004; 229: 567-585.
98. [Shah S, Sylvester PW. Tocotrienol-induced caspase-8 activation is unrelated to death receptor apoptotic signaling in neoplastic mammary epithelial cells. Exp Biol Med 2004; 229: 745-755.
99. Sylvester PW, Shah SJ. Mechanisms mediating the antiproliferative and apoptotic effects of vitamin E in mammary cancer cells.; Front Biosc. 2005; 10: 699-709.
100. Jiang Q, Yin X, Lill MA, Danielson ML, Freiser H, Huang J. Longchain carboxychromanols, metabolites of vitamin E, are potent inhibitors of cyclooxygenases. PNAS: 2008; 105: 20464-20469.
101. Rouzer CA, Marnett LJ. Mechanism of free radical oxygenation of polyunsaturated fatty acids by cyclooxygenases. Chem. Rev. 2003; 103: 2239-2304.
102. Vane JR, Botting RM. Mechanism of action of anti-inflammatory drugs. Int. J Tissue React 1998; 20: 3-15.
103. Coussens LM, Werb Z. Inflammation and Cancer. Nature 2002; 420: 860-867.
104. Wu SJ, Liu PL, Ng LT. Tocotrienol-rich fractiobn of palm oil exhibits anti-inflammatory property by suppressing the expression of inflammatory mediators in human monocytic cells. Mol. Nutr. Food Res. 2008; 52: 921-9.
105. Fang F, Zhanfang Kang Z, Wong C. Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferatoractivated receptors. Mol. Nutr. Food Res. 2010; 54: 345-352.
106. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 1999; 20: 649-688.
107. Puigserver P, Wu, Park CW, Graves R, Wright M, Spiegelman BM. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998; 92: 829-839.
108. Norazlina M, Ima-Nirwana S, Gapor MTA, Khalid BAK. Tocotrienols are needed for normal bone calcification in growing female rats. Asia Pac J Clin Nutr. (2002); 11: 194-9.
109. Qureshi AA, Sami SA, Salser WA, Khan FA. Dose-dependent suppression of serum cholesterol by tocotrienol-rich fraction (TRF25) of rice bran in hypercholesterolemic humans. Atherosclerosis 2002; 161: 199-207.
110. Nazrun AS, Norazlina M, Norliza M, Ima Nirwana S. Comparison of the effects of tocopherol and tocotrienol on osteoporosis in animal models. International journal of pharmacology 2010; 6: 561-568.
111. Norazlina M, Lee P L, Lukman H I, Nazrun A S, Ima-Nirwana S. Effects of vitamin E supplementation on bone metabolism in nicotine treated rats. Singapore Med J 2007; 48: 195-199
112. Cheleuitte D, Mizuno S, Glowacki J. In vitro secretion of cytokines by human bone marrow: effects of age and estrogen status. J Clin Endocrinol Metab 1998; 83: 2043-51.
113. Kurihara N, Suda T, Miura Y, Nakauchi H, Kodama H. et al. Generation of osteoclasts from isolated hematopoietic progenitor cells. Blood 1989; 74: 1295-1302.
114. Papanicolaou DA, Vgontzas AN. Interleukin-6: The endocrine cytokine. J. Clin. Endocrinol. Metab. 2000; 85: 1331-1333.
115. Ahmad NS, Khalid BAK, Luke DA, Ima-Nirwana S. Tocotrienol offers better protection than tocopherol from free radical-induced damage of rat bone. Cin. Exp. Pharm. Physiol. 2005; 32: 761-770.
116. Uto-Kondo H, Ohmori R, Kiyose C, Kishimoto Y, Saito H, Igarashi O, Kondo K. Tocotrienol suppresses adipocyte differentiation and Akt phosphorylation in 3T3-L1 preadipocytes. J. Nutr. 2009; 139: 51-57.
117. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults(Adult Treatment Panel III). 2002 Third report of the National Cholesterol Education Program(NCEP) Expert Panel on Detection Blood Cholesterol in Adults (Adult Treatment Panel III) Final report, Circulation. 2002; 106: 3143-241.
118. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition.Annu. Rev.Med. 1993; 44: 121-31.
119. [Pearson TA, Menash GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, Fadll YY, Fortmann SP, Hong Y, et al. Markers of inflammation and cardiovascular disease: application to clinical and public heath practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation.2003; 107: 499-511.
120. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003; 46: 1594-603.
121. Baliarsingh S, Beg ZH, Ahmad J.The therapeutic impacts of tocotrienols in type 2 diabetic patients with hyperlipidemia. Atherosclerosis 2005; 182: 367-74.
122. Chao JT, Gapor A, Theriault A. Inhibitory Effect of Delta-Tocotrienol, a HMG CoA Reductase Inhibitor, on Monocyte-Endo Thelial Cell Adhesion. J. Nutr. Sci. Vitaminol 2002; 48: 332-337.
123. 2Ames BN, Jiang Q. Jul 15,2008.
124. 1Guthrie N, Kurrowska EM,Carroll KK.Jun 26, 2001.